Galecto raises $295.9M in equity offering; funds Phase 3 of DMR-001

Damora Therapeutics, Inc.

Offering of 14,473,685 shares at $19.00 each; underwriters' option for 2,171,052 additional shares exercised in full.
Net proceeds of approximately $295.9M after underwriting discounts and expenses.
Proceeds intended to fund operations into Phase 3 development of DMR-001.
Underwriting agreement with Jefferies LLC and Leerink Partners LLC; closing expected February 12, 2026.
Offering was made under an automatic shelf registration statement on Form S-3 (File No. 333-293343).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Damora Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC and Leerink Partners LLC, as the representatives of the several underwriters named therein valued at approximately $295.9 million (effective 2026-02-10).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC and Leerink Partners LLC, as the representatives of the several underwriters named therein
Value: approximately $295.9 million
Effective: 2026-02-10

Exact text from the filing

On February 10, 2026, Galecto, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC, as the representatives of the several underwriters named therein (the “Underwriters”), relating to the offer and sale (the “Offering”) of 14,473,685 shares of the Company’s common stock, par value $0.00001 per share (the “Common Stock”), at a public offering price of $19.00 per share.

View on SEC.gov

308 material agreements filed in the last 30 days. Browse all material agreements →

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-046817

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.